"T"-ing off on nasopharynx cancer

Nasopharyngeal carcinoma (NPC) is the most frequent Epstein-Barr virus (EBV)-associated malignancy worldwide. In this issue, Straathof and colleagues take aim at EBV-associated NPC showing that adoptive immunotherapy with EBV-specific T cells expanded in vitro can be successfully administered to NPC patients and is associated with potential therapeutic efficacy.